Shenyang Xingqi Pharmaceutical Co.,Ltd. (SHE: 300573)
China
· Delayed Price · Currency is CNY 87.35
-6.28 (-6.71%)
Oct 11, 2024, 9:30 AM CST
Shenyang Xingqi Pharmaceutical Co.,Ltd. Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Net Income | 321.6 | 240.04 | 211.68 | 194.7 | 87.98 | 35.89 | Upgrade
|
| Depreciation & Amortization | 94.14 | 86.28 | 74.37 | 67.28 | 45.51 | 40.56 | Upgrade
|
| Other Amortization | 8.3 | 7.06 | 5.65 | 6.21 | 3.35 | 3.1 | Upgrade
|
| Loss (Gain) From Sale of Assets | -0.15 | 0.04 | -0.42 | -5.16 | 0.08 | -0.01 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | - | 0 | 0 | - | 4.76 | Upgrade
|
| Loss (Gain) From Sale of Investments | - | - | - | -3.14 | - | - | Upgrade
|
| Provision & Write-off of Bad Debts | 2.09 | 3.03 | 0.93 | -0.19 | 1.04 | - | Upgrade
|
| Other Operating Activities | 11.39 | 10.23 | 5.53 | 24.49 | 14.32 | -1.94 | Upgrade
|
| Change in Accounts Receivable | -153.87 | -104.38 | -37.51 | -33.43 | -61.27 | -47.05 | Upgrade
|
| Change in Inventory | -36.83 | -22.05 | -34.35 | -27.8 | 8.71 | -25.68 | Upgrade
|
| Change in Accounts Payable | 135 | 73.17 | 23.51 | 73.27 | 18.72 | 63.08 | Upgrade
|
| Change in Other Net Operating Assets | 18.11 | 23.42 | 42.47 | 13.31 | 4.19 | 8.92 | Upgrade
|
| Operating Cash Flow | 400.42 | 317.57 | 286.26 | 306.96 | 122.16 | 74.08 | Upgrade
|
| Operating Cash Flow Growth | 56.65% | 10.94% | -6.74% | 151.28% | 64.90% | 68.33% | Upgrade
|
| Capital Expenditures | -189.47 | -261.96 | -299.23 | -95.06 | -108.15 | -69.98 | Upgrade
|
| Sale of Property, Plant & Equipment | 0.02 | 0.02 | 0.08 | 19.03 | 0 | 0.03 | Upgrade
|
| Divestitures | - | - | - | 1.26 | - | - | Upgrade
|
| Investment in Securities | -10 | - | - | -130.24 | - | - | Upgrade
|
| Other Investing Activities | - | - | - | 3 | - | - | Upgrade
|
| Investing Cash Flow | -199.45 | -261.94 | -299.15 | -202.01 | -108.15 | -69.94 | Upgrade
|
| Short-Term Debt Issued | - | 70 | 20 | 100 | 120 | 143 | Upgrade
|
| Total Debt Issued | 250 | 70 | 20 | 100 | 120 | 143 | Upgrade
|
| Short-Term Debt Repaid | - | - | -120 | -80 | -130 | -103 | Upgrade
|
| Long-Term Debt Repaid | - | -7.67 | -6.17 | -8.7 | - | - | Upgrade
|
| Total Debt Repaid | -57.13 | -7.67 | -126.17 | -88.7 | -130 | -103 | Upgrade
|
| Net Debt Issued (Repaid) | 192.87 | 62.33 | -106.17 | 11.3 | -10 | 40 | Upgrade
|
| Issuance of Common Stock | 25.3 | 25.3 | 27.56 | 580.18 | - | - | Upgrade
|
| Repurchase of Common Stock | - | - | - | -0.27 | -0.54 | - | Upgrade
|
| Common Dividends Paid | -465.82 | -178.49 | -80.84 | -47.13 | -16.2 | -20 | Upgrade
|
| Other Financing Activities | 6 | 6.69 | 1.02 | -5.95 | 11.66 | -14.21 | Upgrade
|
| Financing Cash Flow | -241.64 | -84.17 | -158.42 | 538.12 | -15.08 | 5.79 | Upgrade
|
| Foreign Exchange Rate Adjustments | 0.16 | 0.2 | -0.09 | -0.13 | -0.02 | 0.01 | Upgrade
|
| Net Cash Flow | -40.51 | -28.34 | -171.4 | 642.94 | -1.09 | 9.94 | Upgrade
|
| Free Cash Flow | 210.96 | 55.61 | -12.96 | 211.9 | 14.01 | 4.11 | Upgrade
|
| Free Cash Flow Growth | 690.33% | - | - | 1412.86% | 241.17% | - | Upgrade
|
| Free Cash Flow Margin | 12.60% | 3.79% | -1.04% | 20.61% | 2.03% | 0.76% | Upgrade
|
| Free Cash Flow Per Share | 1.20 | 0.32 | -0.08 | 1.32 | 0.09 | 0.03 | Upgrade
|
| Cash Interest Paid | - | - | - | - | - | 4.46 | Upgrade
|
| Cash Income Tax Paid | 148.49 | 109.68 | 134.28 | 103.23 | 73.86 | 65.2 | Upgrade
|
| Levered Free Cash Flow | 141.58 | -20.83 | -104.31 | 127.3 | -12.51 | 9.79 | Upgrade
|
| Unlevered Free Cash Flow | 143.67 | -19.94 | -103.72 | 131.04 | -8.8 | 12.58 | Upgrade
|
| Change in Net Working Capital | 17.91 | 37.19 | 68.98 | 10.91 | 23.76 | -6.55 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.